Literature DB >> 18034018

Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases.

Julian Dutka1, Paweł Sosin.   

Abstract

UNLABELLED: Background. AIMS OF THE STUDY: 1) evaluation of the quality of life of the patients after surgical treatment of bone metastases, 2) evaluation of survival rate of the patients after surgical treatment of bone metastases, <br /> 3) presentation of the authors' clinical score system for evaluation of the treatment results of bone metastases, 4) analysis of general complications rate after surgical treatment of bone metastases. <br /> Material and methods. Retrospective evaluation of 62 patients with bone metastases treated operatively in our Ward during last 13 years was made. Mean age of patients was 63,6 years. There were 41 women (mean age; 62,8 years) and 21 men (mean age: 64,3). In 49 cases (79%) we were able to diagnose primary localization of the tumour: breast carcinoma - 22, ovary cancer - 6, lung cancer - 5, prostate cancer - 5, kidney cancer - 6, gastric cancer - 1, vaginal cancer - 1, hepatocellular cancer - 1, melanoma - 1 and plasmocytoma - 1. We could not reveal primary focus of the tumour in 13 cases (21%). Localizations of bone metastases are as follow: femur - 49 cases, humerus - 10, tibia - 3. After being accepted to operavite treatment, the patients had been cured as quickly as possible - sometimes during emergency service. In 2 cases with metastases in the tibia there were amputations made in femur regions. In remainq patients we made local excisions of metastatic tumours with internal osteosynthesis and bone cement application in 47 cases, with internal osteosynthesis only in 7 cases, with hip arthroplasty in 8 cases. <br /> Results. We have poor results in 4,8%, because of the death of 3 patients. Mean time of follow-up since surgical procedure was 6 months. In 82,3% we have very good or good results - no pain, good function and independence in daily activities. Mean survival time is 17,5 months (range: 5-36 months). <br /> Conclusions. Efficacy of the surgical procedures of pathological fracures due to bone metastases in reliving the pain, improvement of patients' mobility and activiteis of day living are very good. Mean time of survival after surgical treatment of pathological fracture due to bone metastases in study group justifies its applications in spite of higher rate of general complications.<br />

Entities:  

Year:  2003        PMID: 18034018

Source DB:  PubMed          Journal:  Ortop Traumatol Rehabil        ISSN: 1509-3492


  5 in total

1.  [When is surgical treatment indicated in metastatic prostate cancer and what is the scientific rationale?]

Authors:  A Kretschmer; A Herlemann; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

2.  Treatment of pathological humeral shaft fractures with intramedullary nailing. A retrospective study.

Authors:  Juan Pretell; Juan Rodriguez; David Blanco; Alberto Zafra; Carlos Resines
Journal:  Int Orthop       Date:  2009-07-02       Impact factor: 3.075

3.  Management of humeral impending or pathological fractures with intramedullary nailing: reaming versus non reaming technique-a retrospective comparative study.

Authors:  M Younis; S W Barnhill; J Maguire; J Pretell-Mazzini
Journal:  Musculoskelet Surg       Date:  2020-05-25

Review 4.  Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer.

Authors:  Miriam Hegemann; Moritz Maas; Steffen Rausch; Simon Walz; Jens Bedke; Arnulf Stenzl; Tilman Todenhöfer
Journal:  Asian J Androl       Date:  2017-12-29       Impact factor: 3.285

5.  Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction.

Authors:  Jungho Back; Minh Nam Nguyen; Lu Li; Saelim Lee; Inkyu Lee; Fancheng Chen; Lauren Gillinov; Yeon-Ho Chung; Kareme D Alder; Hyuk-Kwon Kwon; Kristin E Yu; Christopher M Dussik; Zichen Hao; Michael J Flores; Yoseph Kim; Izuchukwu K Ibe; Alana M Munger; Sung Wook Seo; Francis Y Lee
Journal:  Bone Res       Date:  2021-09-29       Impact factor: 13.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.